Chirag Paswan says India working with global bodies on nutraceutical regulations

India is actively working with international regulatory bodies, including Codex Alimentarius Commission, to develop essential regulations for the rapidly expanding nutraceutical sector. The government recognizes the immense growth potential and is committed to addressing existing gaps. This initiative aims to foster a structured environment for the industry's advancement, ensuring nutritional security alongside food security for the nation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LTHxBrU
via IFTTT

Read More

Zydus’s weight-loss injection to reach India via Lupin partnership

Zydus Lifesciences and Lupin are joining forces. They will make a generic version of the popular weight-loss and diabetes drug semaglutide more accessible in India. This collaboration follows the upcoming expiry of Novo Nordisk's patent. Lupin will co-market Zydus's semaglutide injection under its own brand. This move aims to reach more patients across the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/duKU36L
via IFTTT

Read More

Zydus, Lupin sign pact to co-market weight-loss Semaglutide injection in India

Zydus Lifesciences and Lupin have joined forces to bring Semaglutide Injection to India. This medication helps manage type 2 diabetes and aids in chronic weight management. This collaboration aims to provide advanced therapies for metabolic disorders across the nation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KkhBqjl
via IFTTT

Read More

SC grills Sebi over lingering probe against Sandesara brothers despite Rs 5,100 cr settlement

In a surprising turn of events, the Supreme Court has scrutinised Sebi's ongoing actions against the directors of Sterling Biotech. This review arises following the directors’ hefty ₹5,100 crore settlement payment. Earlier, the court had invalidated all related cases. Sebi's investigation concerns the suspected routing of funds.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cGoaAPK
via IFTTT

Read More

Sun Pharma’s Ilumya expansion bid gets USFDA nod for review

Sun Pharmaceutical has received a significant approval from the USFDA. The company's innovative drug, Ilumya, is now being considered for treating adults with active psoriatic arthritis. This marks a crucial step for Sun Pharma in expanding its medicine portfolio. The US regulator has accepted the application for review.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3ZMkVv2
via IFTTT

Read More

India pharma production hit by propane shortage; vitamin, hormone supply at risk

India’s pharmaceutical industry is facing the risk of medicine shortages as a propane gas crunch forces several manufacturing units to partially or fully shut operations, disrupting production of key drugs including paracetamol, vitamins and hormones.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zyTPBuk
via IFTTT

Read More

Mankind Pharma targets early Semaglutide launch

Mankind Pharma is set to enter India's semaglutide market soon. The drug's patent expires this month, opening doors for new players. Mankind Pharma plans to offer the medication at affordable prices. This move aims to improve patient access to this important therapy. The company sees a significant opportunity as semaglutide's use extends beyond diabetes to other health areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tyGXjwh
via IFTTT

Read More